Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

NBTX vs ARAY vs ISRG vs NVCR vs MDT

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NBTX
Nanobiotix S.A.

Biotechnology

HealthcareNASDAQ • FR
Market Cap$2.06B
5Y Perf.+158.2%
ARAY
Accuray Incorporated

Medical - Devices

HealthcareNASDAQ • US
Market Cap$35M
5Y Perf.-93.0%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$161.07B
5Y Perf.+66.3%
NVCR
NovoCure Limited

Medical - Instruments & Supplies

HealthcareNASDAQ • JE
Market Cap$1.92B
5Y Perf.-90.3%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$99.94B
5Y Perf.-33.4%

NBTX vs ARAY vs ISRG vs NVCR vs MDT — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NBTX logoNBTX
ARAY logoARAY
ISRG logoISRG
NVCR logoNVCR
MDT logoMDT
IndustryBiotechnologyMedical - DevicesMedical - Instruments & SuppliesMedical - Instruments & SuppliesMedical - Devices
Market Cap$2.06B$35M$161.07B$1.92B$99.94B
Revenue (TTM)$48M$429M$10.58B$674M$35.48B
Net Income (TTM)$-85M$-46M$2.98B$-173M$4.61B
Gross Margin100.0%26.8%66.3%75.2%61.9%
Operating Margin-143.9%-5.1%30.5%-27.2%17.9%
Forward P/E43.8x14.1x
Total Debt$51M$176M$303M$290M$28.52B
Cash & Equiv.$50M$57M$3.37B$103M$2.22B

NBTX vs ARAY vs ISRG vs NVCR vs MDTLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NBTX
ARAY
ISRG
NVCR
MDT
StockDec 20May 26Return
Nanobiotix S.A. (NBTX)100258.2+158.2%
Accuray Incorporated (ARAY)1007.0-93.0%
Intuitive Surgical,… (ISRG)100166.3+66.3%
NovoCure Limited (NVCR)1009.7-90.3%
Medtronic plc (MDT)10066.6-33.4%

Price return only. Dividends and distributions are not included.

Quick Verdict: NBTX vs ARAY vs ISRG vs NVCR vs MDT

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 4 of 7 categories (5-stock set), making it the strongest pick for valuation and capital efficiency and capital preservation and lower volatility. Intuitive Surgical, Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. NBTX also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
NBTX
Nanobiotix S.A.
The Momentum Pick

NBTX ranks third and is worth considering specifically for momentum.

  • +11.9% vs ARAY's -78.4%
Best for: momentum
ARAY
Accuray Incorporated
The Healthcare Pick

ARAY lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
ISRG
Intuitive Surgical, Inc.
The Growth Play

ISRG is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 20.5%, EPS growth 22.6%, 3Y rev CAGR 17.4%
  • 5.5% 10Y total return vs NBTX's 150.9%
  • Lower volatility, beta 1.02, Low D/E 1.7%, current ratio 4.87x
  • PEG 2.01 vs MDT's 36.00
Best for: growth exposure and long-term compounding
NVCR
NovoCure Limited
The Healthcare Pick

Among these 5 stocks, NVCR doesn't own a clear edge in any measured category.

Best for: healthcare exposure
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 36 yrs, beta 0.47, yield 3.6%
  • Better valuation composite
  • Beta 0.47 vs ARAY's 2.42, lower leverage
  • 3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
Best for: income & stability
See the full category breakdown
CategoryWinnerWhy
GrowthISRG logoISRG20.5% revenue growth vs NBTX's -132.1%
ValueMDT logoMDTBetter valuation composite
Quality / MarginsISRG logoISRG28.2% margin vs NBTX's -177.5%
Stability / SafetyMDT logoMDTBeta 0.47 vs ARAY's 2.42, lower leverage
DividendsMDT logoMDT3.6% yield; 36-year raise streak; the other 4 pay no meaningful dividend
Momentum (1Y)NBTX logoNBTX+11.9% vs ARAY's -78.4%
Efficiency (ROA)MDT logoMDT175.8% ROA vs NBTX's -188.4%

NBTX vs ARAY vs ISRG vs NVCR vs MDT — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NBTXNanobiotix S.A.
FY 2024
Other Sales
0.0%$6M
Services
0.0%$-17,534,000
ARAYAccuray Incorporated
FY 2025
Product
51.8%$238M
Service
48.2%$221M
ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
NVCRNovoCure Limited

Segment breakdown not available.

MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B

NBTX vs ARAY vs ISRG vs NVCR vs MDT — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLNBTXLAGGINGMDT

Income & Cash Flow (Last 12 Months)

Evenly matched — NBTX and ISRG each lead in 3 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 740.1x NBTX's $48M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NBTX's -177.5%. On growth, NBTX holds the edge at +186.8% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNBTX logoNBTXNanobiotix S.A.ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
RevenueTrailing 12 months$48M$429M$10.6B$674M$35.5B
EBITDAEarnings before interest/tax-$67M-$15M$3.8B-$165M$9.4B
Net IncomeAfter-tax profit-$85M-$46M$3.0B-$173M$4.6B
Free Cash FlowCash after capex-$33M-$28M$2.8B-$48M$5.4B
Gross MarginGross profit ÷ Revenue+100.0%+26.8%+66.3%+75.2%+61.9%
Operating MarginEBIT ÷ Revenue-143.9%-5.1%+30.5%-27.2%+17.9%
Net MarginNet income ÷ Revenue-177.5%-10.8%+28.2%-25.7%+13.0%
FCF MarginFCF ÷ Revenue-69.2%-6.5%+26.8%-7.1%+15.2%
Rev. Growth (YoY)Latest quarter vs prior year+186.8%-7.4%+23.0%+12.3%+8.8%
EPS Growth (YoY)Latest quarter vs prior year+76.1%-6.1%+18.8%-100.0%-11.9%
Evenly matched — NBTX and ISRG each lead in 3 of 6 comparable metrics.

Valuation Metrics

ARAY leads this category, winning 3 of 7 comparable metrics.

At 21.6x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), ISRG offers better value at 2.65x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.

MetricNBTX logoNBTXNanobiotix S.A.ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
Market CapShares × price$2.1B$35M$161.1B$1.9B$99.9B
Enterprise ValueMkt cap + debt − cash$2.1B$154M$158.0B$2.1B$126.2B
Trailing P/EPrice ÷ TTM EPS-25.18x-18.91x57.62x-13.80x21.60x
Forward P/EPrice ÷ next-FY EPS est.43.84x14.13x
PEG RatioP/E ÷ EPS growth rate2.65x36.00x
EV / EBITDAEnterprise value multiple10.99x43.62x14.32x
Price / SalesMarket cap ÷ Revenue0.08x16.00x2.92x2.98x
Price / BookPrice ÷ Book value/share0.37x9.17x5.51x2.08x
Price / FCFMarket cap ÷ FCF64.67x19.28x
ARAY leads this category, winning 3 of 7 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 6 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-77 for ARAY. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to ARAY's 2.17x. On the Piotroski fundamental quality scale (0–9), ARAY scores 6/9 vs NBTX's 1/9, reflecting solid financial health.

MetricNBTX logoNBTXNanobiotix S.A.ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
ROE (TTM)Return on equity-77.5%+16.9%-50.8%+9.4%
ROA (TTM)Return on assets-188.4%-10.1%+14.8%-16.5%+175.8%
ROICReturn on invested capital+3.0%+15.0%-16.4%+6.0%
ROCEReturn on capital employed-2.6%+2.8%+16.5%-28.9%+7.5%
Piotroski ScoreFundamental quality 0–916656
Debt / EquityFinancial leverage2.17x0.02x0.85x0.59x
Net DebtTotal debt minus cash$1M$119M-$3.1B$187M$26.3B
Cash & Equiv.Liquid assets$50M$57M$3.4B$103M$2.2B
Total DebtShort + long-term debt$51M$176M$303M$290M$28.5B
Interest CoverageEBIT ÷ Interest expense-3.83x-1.86x-96.80x9.08x
ISRG leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

NBTX leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in NBTX five years ago would be worth $28,294 today (with dividends reinvested), compared to $606 for ARAY. Over the past 12 months, NBTX leads with a +1191.2% total return vs ARAY's -78.4%. The 3-year compound annual growth rate (CAGR) favors NBTX at 99.6% vs ARAY's -56.6% — a key indicator of consistent wealth creation.

MetricNBTX logoNBTXNanobiotix S.A.ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
YTD ReturnYear-to-date+92.5%-65.5%-19.3%+28.3%-18.1%
1-Year ReturnPast 12 months+1191.2%-78.4%-15.4%+1.1%-2.8%
3-Year ReturnCumulative with dividends+695.0%-91.8%+49.6%-75.7%-4.2%
5-Year ReturnCumulative with dividends+182.9%-93.9%+58.7%-91.3%-27.7%
10-Year ReturnCumulative with dividends+150.9%-94.5%+554.2%+30.3%+26.5%
CAGR (3Y)Annualised 3-year return+99.6%-56.6%+14.4%-37.6%-1.4%
NBTX leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

Evenly matched — NBTX and MDT each lead in 1 of 2 comparable metrics.

MDT is the less volatile stock with a 0.47 beta — it tends to amplify market swings less than ARAY's 2.42 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NBTX currently trades 95.8% from its 52-week high vs ARAY's 14.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNBTX logoNBTXNanobiotix S.A.ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
Beta (5Y)Sensitivity to S&P 5001.81x2.42x1.02x2.20x0.47x
52-Week HighHighest price in past year$44.46$2.10$603.88$20.06$106.33
52-Week LowLowest price in past year$3.26$0.28$427.84$9.82$77.16
% of 52W HighCurrent price vs 52-week peak+95.8%+14.0%+75.1%+83.9%+73.3%
RSI (14)Momentum oscillator 0–10068.258.442.469.827.3
Avg Volume (50D)Average daily shares traded75K1.4M1.8M1.5M7.8M
Evenly matched — NBTX and MDT each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: NBTX as "Buy", ISRG as "Buy", NVCR as "Buy", MDT as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -34.3% for NBTX (target: $28). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.

MetricNBTX logoNBTXNanobiotix S.A.ARAY logoARAYAccuray Incorpora…ISRG logoISRGIntuitive Surgica…NVCR logoNVCRNovoCure LimitedMDT logoMDTMedtronic plc
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$28.00$622.60$33.50$109.50
# AnalystsCovering analysts2551549
Dividend YieldAnnual dividend ÷ price+3.6%
Dividend StreakConsecutive years of raises36
Dividend / ShareAnnual DPS$2.78
Buyback YieldShare repurchases ÷ mkt cap0.0%0.0%+1.4%0.0%+3.2%
Insufficient data to determine a leader in this category.
Key Takeaway

ARAY leads in 1 of 6 categories (Valuation Metrics). ISRG leads in 1 (Profitability & Efficiency). 2 tied.

Best OverallNanobiotix S.A. (NBTX)Leads 1 of 6 categories
Loading custom metrics...

NBTX vs ARAY vs ISRG vs NVCR vs MDT: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NBTX or ARAY or ISRG or NVCR or MDT a better buy right now?

For growth investors, Intuitive Surgical, Inc.

(ISRG) is the stronger pick with 20. 5% revenue growth year-over-year, versus -132. 1% for Nanobiotix S. A. (NBTX). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Nanobiotix S. A. (NBTX) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NBTX or ARAY or ISRG or NVCR or MDT?

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Intuitive Surgical, Inc. wins at 2. 01x versus Medtronic plc's 36. 00x.

03

Which is the better long-term investment — NBTX or ARAY or ISRG or NVCR or MDT?

Over the past 5 years, Nanobiotix S.

A. (NBTX) delivered a total return of +182. 9%, compared to -93. 9% for Accuray Incorporated (ARAY). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus ARAY's -94. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NBTX or ARAY or ISRG or NVCR or MDT?

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

47β versus Accuray Incorporated's 2. 42β — meaning ARAY is approximately 419% more volatile than MDT relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 2% for Accuray Incorporated — giving it more financial flexibility in a downturn.

05

Which is growing faster — NBTX or ARAY or ISRG or NVCR or MDT?

By revenue growth (latest reported year), Intuitive Surgical, Inc.

(ISRG) is pulling ahead at 20. 5% versus -132. 1% for Nanobiotix S. A. (NBTX). On earnings-per-share growth, the picture is similar: Accuray Incorporated grew EPS 90. 3% year-over-year, compared to -33. 3% for Nanobiotix S. A.. Over a 3-year CAGR, ISRG leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NBTX or ARAY or ISRG or NVCR or MDT?

Nanobiotix S.

A. (NBTX) is the more profitable company, earning 586. 9% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 586. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NBTX leads at 589. 1% versus -23. 5% for NVCR. At the gross margin level — before operating expenses — NBTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NBTX or ARAY or ISRG or NVCR or MDT more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Intuitive Surgical, Inc. (ISRG) is the more undervalued stock at a PEG of 2. 01x versus Medtronic plc's 36. 00x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 29. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for NVCR: 99. 0% to $33. 50.

08

Which pays a better dividend — NBTX or ARAY or ISRG or NVCR or MDT?

In this comparison, MDT (3.

6% yield) pays a dividend. NBTX, ARAY, ISRG, NVCR do not pay a meaningful dividend and should not be held primarily for income.

09

Is NBTX or ARAY or ISRG or NVCR or MDT better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

47), 3. 6% yield). Accuray Incorporated (ARAY) carries a higher beta of 2. 42 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MDT: +26. 5%, ARAY: -94. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NBTX and ARAY and ISRG and NVCR and MDT?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NBTX is a small-cap quality compounder stock; ARAY is a small-cap quality compounder stock; ISRG is a mid-cap high-growth stock; NVCR is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock. MDT pays a dividend while NBTX, ARAY, ISRG, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

NBTX

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 93%
  • Gross Margin > 60%
Run This Screen
Stocks Like

ARAY

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 16%
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

NVCR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 6%
  • Gross Margin > 45%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform NBTX and ARAY and ISRG and NVCR and MDT on the metrics below

Revenue Growth>
%
(NBTX: 186.8% · ARAY: -7.4%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.